Several major vape manufacturers have filed motions to join an existing lawsuit challenging the U.S. Food and Drug Administration’s May 2026 enforcement guidance for electronic nicotine delivery systems (ENDS). The companies—AVM, Altria’s Helix brand, NJOY, and USA Vape Lab—seek intervenor status in a case that argues the guidance oversteps FDA authority and risks unlawful product removals from the market.
Executive summary
Four prominent ENDS manufacturers are seeking to join a legal challenge against the FDA’s May 2026 enforcement guidance, which outlines how the agency intends to prioritize regulatory actions against unauthorized vaping products. The movants claim the guidance creates unacceptable uncertainty and could lead to premature withdrawals of products currently in legal limbo.
What happened
On October 10, 2026, AVM, Helix (owned by Altria), NJOY, and USA Vape Lab filed motions to intervene in a lawsuit originally brought by a coalition of smaller vape retailers and distributors. The suit, filed in the U.S. District Court for the District of Columbia, contests the FDA’s May 15, 2026, guidance document titled "Enforcement Priorities for Electronic Nicotine Delivery Systems." The guidance states that the FDA may take enforcement action against any ENDS product not authorized via the Premarket Tobacco Product Application (PMTA) process, including those with pending applications or those marketed before the 2020 statutory deadline without authorization.
Why it matters
The FDA’s enforcement guidance has significant implications for market stability, as it signals how aggressively the agency intends to clear the market of unauthorized products ahead of completing its PMTA review backlog. Over 90% of ENDS products currently sold in the U.S. lack FDA authorization, though many have submitted PMTAs that remain under review. The guidance could accelerate removals before scientific reviews are complete, affecting product availability and creating supply chain disruptions.
Market impact
If the court sides with the challengers and limits the FDA’s enforcement reach, it could prolong the current regulatory gray market for ENDS products, delaying the transition to a fully authorized product landscape. Conversely, if the guidance is upheld, manufacturers with pending PMTAs may face abrupt market exits, potentially consolidating share among the fewer brands that have secured authorization—or those able to withstand prolonged legal challenges.
Regulatory signal: The FDA’s enforcement guidance reflects a shift toward market clearance regardless of PMTA review timelines, increasing legal risk for products in review.
Regulatory impact
A ruling restricting the FDA’s ability to enforce against products with pending PMTAs would constrain the agency’s tools for addressing the unauthorized ENDS market, potentially extending the period of regulatory uncertainty. It could also prompt the FDA to issue new guidance or pursue rulemaking to clarify its authority, though any such action would face similar judicial scrutiny.
Who is affected
- Manufacturers with PMTAs under review (including Helix, NJOY, and USA Vape Lab)
- Retailers and distributors relying on products not yet authorized
- Consumers using ENDS products that may be subject to removal
- State tax authorities reliant on vape product sales for revenue
Dawsen Take
The move by major vape players to defend the FDA’s enforcement guidance—while simultaneously seeking to shape its legal boundaries—highlights the industry’s strategic pivot from opposing regulation outright to managing its execution. Rather than challenging the FDA’s authority to regulate ENDS, these companies are focusing on ensuring enforcement aligns with statutory processes, particularly the PMTA review timeline. This reflects a maturation of industry engagement with FDA oversight, where predictability and procedural fairness are now central concerns.
Market impact: Legal clarity on enforcement timing could determine which brands survive the transition to a fully authorized ENDS market.
What to watch
- The court’s decision on the motions to intervene, expected within 60 days
- Any preliminary rulings on the legality of the FDA’s enforcement guidance
- Whether the FDA issues updated guidance or pursues formal rulemaking in response to litigation
- PMTA review timelines for major brands currently under consideration
- Retailer inventory adjustments in anticipation of potential market shifts
For more daily vaping news, check out dawsenai.com
Original source: Vape makers line up to defend FDA's enforcement guidance
For more daily vaping news, check out dawsenai.com.
Written by
Comments
